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The previous results suggest that peroxisome proliferator-activated receptor-alpha (PPAR)-α, an intracellular transcription factor
activatedbyfattyacids,playsaroleincontrolofinﬂammation.Thereispersuasiveepidemiologicalandexperimentalevidencethat
dietary polyphenols have anti-inﬂammatory activity. In this regard, it has been demonstrated that verbascoside (VB) functions
as intracellular radical scavenger and reduces the microscopic and macroscopic signs of experimental colitis. With the aim to
characterize the role of PPAR-α in VB-mediated anti-inﬂammatory activity, we tested the eﬃcacy of VB in an experimental model
of inﬂammatory bowel disease induced by dinitrobenzene sulfonic acid, comparing mice lacking PPAR-α (PPAR-αKO) with wild
type (WT) mice. Results indicate that VB-mediated anti-inﬂammatory activity is weakened in PPAR-αK Om i c e ,c o m p a r e dt oW T
controls, especially in the inhibition of neutrophil inﬁltration, intestinal permeability and colon injury. These results indicate that
PPAR-α can contribute to the anti-inﬂammatory activity of VB in inﬂammatory bowel disease.
1.Introduction
The inﬂammatory bowel diseases (IBDs) has a worldwide
distribution, its pathogenesis is not clearly understood [1].
A major advance in the study of IBD has been the discovery
and subsequent analysis of a number of models of mucosal
inﬂammation that resemble IBD [2]. Recently, Blumberg
and colleagues [3] have indicated that these models fall
into four main categories (spontaneous, administration of
exogenousagents,gene-targetedknockoutortransgenic,and
transfer of cells into immunodeﬁcient animals) and each
provides unique opportunities to discover insights into the
nature of the pathogenesis of IBD. Dinitrobenzene sulfonic
acid (DNBS)—induced colitis in experimental animals (e.g.,
mouse and rats) has proven to be a useful model of IBD,
as it possesses many of the cell and humoral immunity
characteristics found in human IBD [4].
Peroxisome proliferator-activated receptor (PPAR)-α is
an intracellular transcription factor, activated by fatty acids,
which play a role in inﬂammation [5]. PPARs are expressed
in the intestine at various levels [6]. Recently, it has been
demonstrated that PPAR-α is also expressed in the digestive
tract mainly localized in the intestinal mucosa, in the small
intestine, and in the colon [6]. In particular, it has been
demonstrated that there is a higher expression of PPAR in
the more diﬀerentiated colonic epithelial cells facing the
intestinal lumen as compared to cells in the lower parts of
the crypts [7].
In addition, it has been reported that PPAR-α acti-
vation can result in inhibition of nuclear factor (NF)-
κB activation and inﬂammatory genes expression [8]. Our
recent results in diseases models of colitis and pleurisy
show that mice lacking PPAR-α (PPAR-αKO) develop an
increased inﬂammation as compared to wild type (WT)2 PPAR Research
mice. Moreover, treatment with appropriate doses of PPAR-
α agonists can inhibit inﬂammatory diseases development
[9].
Phenylpropanoid glycosides (PPGs, also synonymous of
phenylethanoid glycosides) are water soluble derivatives of
phenylpropanoids (PPs), a large group of natural polyphe-
nols widely distributed in the plant kingdom [10]. There is
growing evidence that PPGs, like other plant polyphenols
in general and PPs in particular, are powerful antioxidants
either by direct scavenging of reactive oxygen and nitrogen
species, or by acting as chain-breaking peroxyl radical
scavengers [11]. Recently, PPs have been reported to be
eﬀective in the chemoprevention of tumors [10]a sw e l l
as to have antithrombotic, wound healing, and cardio-
protective actions [12]. There is now growing interest in
the biotechnological approach to produce plant-derived
active substances using nongenetically modiﬁed plant cell
cultures [13]. Verbascoside (VB), containing a rhamnose
unit bound to glucose which acts as a bridge, belongs to
the extensive family of PPs, a class of plant-derived organic
compounds that are biosynthesized from the amino acid
phenylalanine. Recently, it has been demonstrated that VB
promotes skin repair and ameliorates skin inﬂammation due
to their ROS scavenging, antioxidant, iron chelating, and
glutathione transferase (GST) activity inducing properties
[14]. Moreover, we have recently demonstrated that VB from
Syringa vulgaris IRBSV25/B cell cultures exerted protection
on the chronic inﬂammatory response (colitis) caused by
injection of DNBS in the rat [15].
With the aim to characterize the role of PPAR-α in VB-
mediatedanti-inﬂammatoryactivity,wetestedtheeﬃcacyof
VB in an experimental model of inﬂammatory bowel disease
induced by DNBS, comparing PPAR-αKO and WT mice.
Results indicate that in a chronic situation like inﬂammatory
bowel disease, VB-mediated anti-inﬂammatory activity is
weakened in PPAR-αKO mice compared to WT controls.
2.MaterialsandMethods
2.1. Animals. Mice (4-5 weeks old, 20–22g) with a targeted
disruption of the PPAR-α gene (PPAR-αKO) and littermate
wild-type controls (PPAR-αWT) were purchased from Jack-
son Laboratories (Harlan Nossan, Italy). Mice homozygous
for the PparatniJGonz−targeted mutation mice are viable,
fertile, and appear normal in appearance and behavior. Exon
eight, encoding the ligand-binding domain, was disrupted
by the insertion of a 1.14kb neomycin resistance gene in
the opposite transcriptional direction. After electroporation
of the targeting construct into J1 ES cells, the ES cells were
injectedintoC57BL/6Nblastocysts.Thisstainwascreatedon
B6,129S4 background, and is maintained as a homozygote
on a 129S4/SvJae background by brother sister matings.
The animals were housed in a controlled environment and
provided with standard rodent chow and water. Animal
care was carried out in compliance with Italian regulations
on protection of animals used for experimental and other
scientiﬁc purposes (D.M. 116192) as well as with the EEC
regulations (O.J. of E.C. L 358/112/18/1986).
2.2. Plant Cell Line. The Syringa vulgaris plant utilized by
IRB to originate the cell line derives from the Botanical
Garden of the University of Bologna, Bologna, Italy. The
stabilized and highly selected cell line with high content
of VB was obtained from dissected young Syringa vulgaris
leaves sterilized by NaOCl and Tween 20. The stabilized
and selected cell line was deposited at the Plant Cell
Bank (DSMZ, Deutsche Sammlung Von Mikroorganismen
und Zellkulturen, Braunschweig, Germany) coded internally
IRBSV25/B and internationally DSM 16857. The IRBSV25/B
plant cell line was used for the industrial culture fermentors.
2.3. VB Containing Extract Preparation. Syringa vulgaris
IRBSV25/B cell cultures obtained at the end of the fermen-
tation process were collected and mechanically homogenized
by Ultraturrax. The solid residue, mainly cellular debris, was
then separated from the aqueous phase containing VB by
centrifugation at 1.000×g for 10 minutes. The yield of VB
was approx. 3g/L of the plant cell culture liquid suspension.
The VB in the supernatant was recovered by solid phase
extraction on XAD4 resin, followed by elution with 80/20
ethanol/water (V/V) mixture. Then, the eluted VB was
concentrated under reduced pressure and lyophilized. The
ﬁnal extract, a pale yellow powder, contained VB in an
amount over 80% (w/w), together with minor admixture
(>10%w/w) of other caﬀeic acid derivatives. The further
puriﬁcation of VB was performed by repeated column
chromatography on C18 silica gel and Sephadex LH20 and
subsequent crystallization obtaining a ﬁnal product with VB
content above 97% (w/w). The standard raw extract with a
purity of 50 ± 1% (w/w) was obtained from the 80% (w/w)
cell extract by addition of maltodextrins.
2.4. HPLC Analysis. The analysis was performed using
HPLC system (Agilent, series 1100 DAD, Hewlett-Packard)
consisting of an autosampler, high pressure mixing pump,
and the column C18 (2) Phenomenex 4.6 × 150mm. The
gradientsystemwasPhaseA—water/0.01Nphosphoricacid;
and Phase B: acetonitryl/0.01N phosphoric acid.
The reference product used to set up the quantitative
method has been internally prepared by IRB. The chemical
structure of the product has been determined and conﬁrmed
by means of mass spectrometry (MS) and nuclear magnetic
resonance (NMR) at the Department of Organic Chemistry
of the University of Milan. The NMR spectra were recorded
in CD3OD solvent on a Bruker Avance 400 instrument.
T h ec a l i b r a t i o nc u r v eo ft h ev e r b a s c o s i d ew a si ng o o d
linearity over the range of 20μg/mL–150μg/mL (r =
0,9997) and the average recoveries of verbascoside were
99.2% (n = 5, RSD 0.23%).
2.5. Experimental Groups. Mice were randomly allocated
into the following groups: (i) PPAR-αWT DNBS + vehicle
group. PPAR-αWT mice were subjected to DNBS-induced
colitis plus administration of saline (N = 10); (ii) PPAR-
αKO DNBS + vehicle group. PPAR-αKO mice were subjected
to DNBS-induced colitis plus administration of saline (N =
10); (iii) PPAR-αWT+VB group. PPAR-αWT were subjectedPPAR Research 3
to DNBS-induced colitis and VB (2mg/kg dissolved in
saline) was given by gavage every 24 hour, starting from
3 hours after the administration of DNBS (N = 10); (iv)
PPAR-αKO+VB group. PPAR-αKO were subjected to DNBS-
induced colitis and VB (2mg/kg dissolved in saline) was
given by gavage every 24 hour, starting from 3 hours after
the administration of DNBS (N = 10); (v) PPAR-αWTSham
+v e h i c l e .PPAR-αWT mice were subjected to the surgical
proceduresastheabovegroupsexceptthat50%ethanolwere
administered to the mice (N = 10); (vi) PPAR-αKO Sham
+v e h i c l e .PPAR-αKO mice were subjected to the surgical
procedures as the above groups except that 50% ethanol
were administered to the mice (N = 10), (vii) PPAR-αWT
Sham + VB group. Identical to PPAR-αWT Sham + saline
group except for the administration of VB group; and (viii)
PPAR-αKO Sham + VB group. Identical to PPAR-αKO Sham
+ saline group except for the administration of VB.
2.6. Induction of Experimental Colitis. Colitis was induced
with a very low dose of DNBS (4mg per mouse) by using
a modiﬁcation of the method ﬁrst described in rats [16].
In preliminary experiments, this dose of DNBS was found
to induce reproducible colitis without mortality. Mice were
anesthetized by enﬂurane. DNBS (4mg in 100μl of 50%
ethanol) was injected into the rectum through a catheter
inserted 4.5cm proximally to the anus. Carrier alone (100μl
of 50% ethanol) was administered in control experiments.
Thereafter, the animals were kept for 15 minutes in a Tren-
delenburg position to avoid reﬂux. After colitis induction,
the animals were observed for 3 days. On Day 4, the animals
were weighed and anaesthetized with chloral hydrate, and
the abdomen was opened by a midline incision. The colon
was removed, freed from surrounding tissues, opened along
the antimesenteric border, rinsed, weighed, and processed
for histology and immunohistochemistry. Colon damage
(macroscopic damage score) was evaluated and scored
by two independent observers according to the following
criteria: 0, no damage; 1, localized hyperemia without ulcers;
2, linear ulcers with no signiﬁcant inﬂammation; 3, linear
ulcers with inﬂammation at one site; 4, two or more major
sites of inﬂammation and ulceration extending >1cmalong
the length of the colon; and 5–8, one point is added for each
centimeter of ulceration beyond an initial 2cm.
2.7. Light Microscopy. A f t e rﬁ x a t i o nf o r1w e e ka tr o o m
temperature in Dietrich solution (14.25% ethanol, 1.85%
formaldehyde, and 1% acetic acid), samples were dehydrated
in graded ethanol and embedded in Paraplast (Sherwood
Medical, Mahwah, New Jersey). Thereafter, 7-μms e c t i o n s
were deparaﬃnized with xylene, stained with haematoxylin-
eosin, and observed in a Dialux 22 Leitz (Wetziar, Germany)
microscope. In order to have a quantitative estimation of
colon damage, section (n = 6 for each animal) was scored
by 2 independent observers blinded to the experimental
protocol.
2.8. Myeloperoxidase Activity. At 4 days after intracolonic
injection of DNBS, the colon was removed and weighed.
The colon was analyzed for myeloperoxidase (MPO) activ-
ity, an indicator of polymorphonuclear leukocyte (PMN)
accumulation, as previously described [17]. MPO activity
was deﬁned as the quantity of enzyme degrading 1μmol of
peroxide per min at 37◦C and was expressed in milliunits per
gram weight of wet tissue.
2.9. Intestinal Permeability. On the 4th day of the experi-
ment, mannitol 5mg and lactulose dissolved in 0.5ml of
normal saline were gavaged. Individual mice were then
immediately placed in metabolic cages to allow for collection
ofurinefor4to5hoursaspreviouslydescribed[18].Urinary
sugar excretion was assessed by gas-liquid chromatography.
2.10.WesternBlotAnalysisforPPAR-α. Nuclear extracts were
prepared as previously described [19] with slight modiﬁca-
tions. PPAR-α expression was quantiﬁed in nuclear fraction
by Western blot analysis. The ﬁlters were blocked with 1x
PBS, 5% (w/v) nonfat dried milk (PM) for 40 minutes at
room temperature and subsequently probed with speciﬁc
Abs against PPAR-α (1:500; Santa Cruz Biotechnology) in
1x PBS, 5% w/v nonfat dried milk, 0.1% Tween-20 (PMT) a
4◦C, overnight. Membranes were incubated with peroxidase-
conjugated bovine antimouse IgG secondary antibody or
peroxidase-conjugated goat antirabbit IgG (1:2000, Jackson
ImmunoResearch, West Grove, PA) for 1 hour at room
temperature. To ascertain that blots were loaded with equal
amounts of protein lysates, they were also incubated in the
presence of the antibody against lamin A/C protein (1:5,000
Sigma-Aldrich Corp.).
2.11. Reagents. Biotin-blocking kit, biotin-conjugated goat
antirabbit IgG, and avidin-biotin peroxidase complex were
obtained from Vector Laboratories (Burlingame, CA, USA).
Primary antinitrotyrosine antibody was purchased from
Upstate Biotech (Saranac Lake, NY, USA). Primary ICAM-
1 (CD54) for immunoistochemistry was purchased by
Pharmingen. Reagents and secondary and nonspeciﬁc IgG
antibody for immunohistochemical analysis were from Vec-
torLaboratoriesInC.Allotherreagentsandcompoundsused
were obtained from Sigma Chemical Company.
2.12. Statistical Analysis. All values in the ﬁgures and text
are expressed as mean ± SEM of N observations, where n
representsthenumberofanimalsstudied.Intheexperiments
involving histology or immunohistochemistry, the ﬁgures
shown are representative of at least 3 experiments performed
on diﬀerent experimental days. Data sets were examined by
one- and two-way analysis of variance and individual group
means were then compared with Student’s unpaired t-test.
Nonparametric data were analyzed with the Fisher’s exact
test. A P-value less than .05 was considered signiﬁcant.
3. Results
3.1. Eﬀects of VB Treatment on PPAR-α Expression in Colon
Tissues. Previous studies have demonstrated an important4 PPAR Research
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Figure 1: Western blot analysis for PPAR-α in nuclear extracts.
By Western blot analysis, a basal level of PPAR-α expression
was detected in colon tissues from sham-operated mice ((a) and
(b)). Four days after DNBS administration, PPAR-α expression
was signiﬁcantly reduced. VB treatments signiﬁcantly reduced
the DNBS-induced inhibition of PPAR-α expression. The relative
expression of the protein bands was standardized for densitometric
analysis to lamin A/C levels and reported in (b) expressed as mean
± s.e.m. from n = 5/6 colon for each group. ∗P<. 01 versus Sham;
◦P<. 01 versus DNBS-WT group.
role for PPAR-α in experimental colitis [15]a n dh a v e
hypothesized that the ability of VB to reduce inﬂammation
may be dependent on activation of PPAR-α.T h u s ,w e
evaluated PPAR-α expression in the nuclear fractions from
colon tissue by Western Blot analysis. A basal level of PPAR-
α was detected in colon tissue from sham-treated mice,
whereas PPAR-α levels were substantially reduced in DNBS-
treated mice (Figure 1(a) and 1(b)). The eﬀect of DNBS was
signiﬁcantly reduced by VB administration (Figure 1(a) and
1(b)).
3.2.RoleofFunctionalPPAR-αGeneintheAnti-Inﬂammatory
Activity of VB on the Degree of Colitis. Four days after intra-
colonic administration of DNBS, the colon appeared ﬂaccid
and ﬁlled with liquid stool. The macroscopic inspection of
cecum, colon, and rectum showed presence of mucosal con-
gestion, erosion, and hemorrhagic ulcerations (Figure 2(b),
see macroscopic score Figure 2(f)). The histopathological
features included a transmural necrosis and edema and a
diﬀuse leukocyte cellular inﬁltrate in the submucosa of colon
section from DNBS-treated PPAR-αWT mice (Figure 3(b),
see histological score Figure 3(f)). The observed inﬂamma-
tory changes of the large intestine were associated with an
increaseintheweightofthecolon(Figure 4(a)).Theabsence
ofPPAR-α genesigniﬁcantlyincreasestheextentandseverity
of the macroscopic signs (Figure 2(c), see macroscopic
score Figure 2(f)), histological indications of colon injury
(Figure 3(c), see histological score Figure 3(f)), as well as the
colon weight (Figure 4(a)). Four days after colitis induced
by DNBS treatment, all mice had diarrhea and a signiﬁcant
reduction in body weight (compared with the control groups
of mice). Absence of a functional PPAR-α gene in PPAR-
αKO mice resulted in a signiﬁcant augmentation of lost of
body weight (Figure 4(b)). No macroscopic (Figure 2(a),s e e
macroscopic score Figure 2(f)) or histological (Figure 3(a),
see macroscopic score Figure 3(f)) alteration was observed
in the colon tissue from vehicle-treated PPAR-αWT and
PPAR-αKO mice. On the other hand, the treatment of
PPAR-αWT with VB resulted in a signiﬁcant decrease in
the extent and severity of the macroscopic (Figure 2(d),s e e
macroscopic score Figure 2(f)), histological signs of colon
injury (Figure 2(d), see macroscopic score Figure 2(f)), the
colon weight (Figure 3(a)), and the lost of body weight
(Figure 3(b)). The genetic absence of the PPAR-α receptor
signiﬁcantlyblockedthebeneﬁcialeﬀectofVB(Figures2and
3, see macroscopic score Figures 2(f) and 3(f)).
3.3. Role of PPAR-α in VB-Induced Inhibition of PMN Inﬁl-
tration. The colitis caused by DNBS was also characterized
by an increase in myeloperoxidase activity, an indicator of
the neutrophils’ accumulation in the colon (Figure 5). This
ﬁnding is consistent with our observation made with light
microscopy that the colon from vehicle-treated DBNS-rats
contained a large number of neutrophils. In PPAR-αKO
mice,colonmyeloperoxidaseactivitywasmarkedlyincreased
in comparison to those of PPAR-αWT animals (Figure 5).
On the contrary, VB signiﬁcantly reduced the degree of
PMNinﬁltration(determinedasincreaseinMPOactivity)in
inﬂamed colon. The genetic absence of the PPAR-α receptor
signiﬁcantly blunted the eﬀect of the VB on the neutrophil
inﬁltration (Figure 5).
3.4. Intestinal Permeability. For assessing baseline small
bowelpermeability,permeabilityprobes(lactuloseandman-
nitol) were administered by gavage, and urinary lactulose
and mannitol excretion were measured in urine collected
over a 4- to 5-hour post gavage period and L/M ratios were
calculated. As indicated in Figure 6, the L/M ratios were
unchanged in the sham PPAR-αWT and in sham PPAR-αKO
mice. On the contrary, in the urinary samples from PPAR-
αWT mice injected with DNBS L/M ratios were signiﬁcantly
higher in comparison to the sham animals. The absence of
PPAR-α in mice (animals with the PPAR-αKO phenotype)
resulted in a pronounced increase of L/M ratios (Figure 6).
On the contrary, VB signiﬁcantly reduced the increase in
L/M ratios. The genetic absence of the PPAR-α receptor
signiﬁcantly blocked the eﬀect of the VB on L/M ratios
(Figure 6).PPAR Research 5
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Figure 2: Role of PPAR-α in the anti-inﬂammatory property of VB on clinical expression of DNBS-induced colitis and macroscopic damage
score. Colon tissues from sham-treated mice (a), colon tissues from DNBS-treated PPAR-αWT (b) or DNBS-treated PPAR-αKO mice (c)
from mice at 4 days post DNBS administration, and the colon tissues collected from DNBS-treated mice which have received VB treatment
(d). The treatment of PPAR-αWT with VB resulted in a signiﬁcant decrease in the extent and severity of the macroscopic signs (d). The
g e n e t i ca b s e n c eo ft h eP P A R - α receptor signiﬁcantly reduced the eﬀect of the VB treatment (e). The macroscopic damage score was made by
two independent observers (f). Data are means ± SEM of 10 mice for each group. ∗P<. 01 versus Sham; ◦P<. 05 versus DNBS-WT group.
4. Discussion
In the present paper, we show that the absence of PPAR-α in
mice results in a reduced anti-inﬂammatory response to VB
treatment in an IBD model. These results are in agreement
with our previous observations indicating that PPAR-αKO
mice are more susceptible to induction of inﬂammatory
bowel disease [20].
There is growing interest in the role of complementary
and alternative medicine (CAM) in health and disease. There
are a myriad of CAM treatments that may prove beneﬁcial
for patients with IBD. Unfortunately, the scientiﬁc basis for
the use of these modalities frequently is lacking, and safety
has not been assessed. Recently, we have demonstrated that
VB from Syringa vulgaris IRBSV25/B cell cultures attenuates
DNBS-induced colitis in the rats, a well-established model of
acute intestinal inﬂammation with some shared features of
Crohn’s disease [15].
Various studies have regarded polyphenols as PPAR
ligands [21]. In particular they have demonstrated that
genistein increases the expression of genes involved in lipid
catabolism in a PPARα-dependent mechanism [22]. More-
over, it has been also demonstrated that epigallocatechin-3-
gallate (EGCG) binds PPAR-α [21]. Therefore, other studies
have also demonstrated that amentoﬂavone upregulated
PPAR-γ expression in A549 human lung cell as well as that
curcumin dramatically induced the expression of PPAR-γ at
levels of transcription and translation [23].6 PPAR Research
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Figure 3: No histological alteration was observed in the colon section from sham-operated mice (a). Mucosal injury was produced after
DNBS administration characterized by absence of epithelium and a massive mucosal and submucosal inﬁltration of inﬂammatory cells (b).
Treatment with VB corrected the disturbances in morphology associated with DNBS administration in PPAR-αWT (c). The absence of
PPAR-α gene signiﬁcantly increases the extent and severity of the histological signs of colon injury (d). The genetic absence of the PPAR-α
receptor signiﬁcantly reduced the eﬀect of the VB treatment (e). The histological score (f) was made by two independent observers. Figure 3
is representative of at least 3 experiments performed on diﬀerent experimental days. Data are means ± SEM of 10 mice for each group.
∗P<. 01 versus Sham; ◦P<. 05 versus DNBS-WT group.
These ﬁndings implied a potential therapeutic value of
PPARsligandsin treatmentof inﬂammatorydisease[24,25].
PPAR-α itself is also able to directly mediate some anti-
inﬂammatory eﬀects and it has been shown that agonist-
induced activation inhibits a number of inﬂammatory
parameters including TNF-α production, iNOS, COX-2, and
adhesion molecule expression as well cell inﬁltration in the
tissues [5].
Based on these observations, we performed studies in the
attempt to determine whether the presence and/or the stim-
ulation of PPAR-α could enhance the VB anti-inﬂammatory
eﬃcacy. For this purpose, we used an experimental model ofPPAR Research 7
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Figure 4: Role of PPAR-α in the anti-inﬂammatory property of VB on colon weight and body weight lost. Four days after DNBS
administration a signiﬁcant increase in colon weight (a) and body weight lost (b) was observed. Treatment with VB signiﬁcantly reduced
the increased colon weight and lowered body weight lost. The absence of PPAR-α gene signiﬁcantly abolished the eﬀe c to fV B .Figure 4 is
representative of all the animals in each group. Data are means ± SEM of 10 mice for each group. ∗P<. 01 versus Sham; ◦P<. 01 versus
DNBS-WT group.
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Figure 5: Eﬀect of endogenous PPAR-α on neutrophil inﬁltration.
Myeloperoxidase (MPO) activity was signiﬁcantly increased in
DNBS-treated PPAR-αWT mice in comparison to SHAM. MPO
activity was signiﬁcantly enhanced in DNBS-treated PPAR-αKO
mice. Treatment with VB signiﬁcantly reduced the colon MPO
activity. The genetic absence of the PPAR-α receptor signiﬁcantly
blocked the eﬀect of VB treatment. Data are means ± SEM of 10
mice for each group. ∗P<. 01 versus sham; ◦P<. 01 versus DNBS
WT.
inﬂammatory bowel disease induced by DNBS using PPAR-
αKO mice compared to WT.
VB-type phenolic ester glycosides showed various bio-
logical activities, from antibiotic and antifeedant to immun-
odepressive. Moreover, VB exhibits antioxidative eﬀects [26]
and antibacterial [27]. VB has been also shown to modulate
nitricoxide(NO)productionandtheexpressionofinducible
nitric oxide synthase (iNOS) in activated macrophages [28,
29]. It also inhibits histamine, arachidonic acid release,
and prostaglandin E2 production in RBL-2H3 mast cells
suggesting a possible application of the compound as anti-
inﬂammatory remedy [30].
In the present study, we have clearly conﬁrmed that the
increasedcoloninjuryinthecolontissuefromDNBS-treated
PPAR-αKO mice correlated with the enhanced leukocyte
inﬁltration, as assessed by the speciﬁc granulocyte enzyme
myeloperoxidase. These observations are in agreement with
ap r e v i o u ss t u d y[ 20]. Moreover, in the present study we
clearly demonstrate that when WT and PPAR-αKO mice
were treated with VB, a signiﬁcant inhibition of neutrophils
inﬁltration as well as tissue injury was observed in WT but
not in PPAR-αKO mice.
Furthermore,intestinalpermeabilityreﬂectstheintegrity
of the intestinal mucosal barrier, which restricts the passive
permeation of luminal substances [31]. It is well known
that altered intestinal permeability has been reported in8 PPAR Research
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Figure 6:EﬀectsofPPAR-αonintestinalpermeability.Permeability
probes (lactulose and mannitol) were administered by gavage,
and urinary lactulose and mannitol excretion were measured in
urine collected over a 4- to 5-hour postgavage period, and L/M
ratios were calculated. The L/M ratio was unchanged in the sham-
treated mice. On the contrary, at 4 days after colitis, the L/M
ratios were signiﬁcantly higher in the urinary samples from DNBS-
treatedPPAR-αWTmiceincomparisonwiththeshamanimals.The
absence of a functional PPAR-α gene in PPAR-αKO mice resulted
in a more pronounced increase of L/M ratios. Treatment with VB
signiﬁcantly reduced the increased L/M ratios, while the absence of
PPAR-αgenesigniﬁcantlyabolishedtheeﬀectofVB.Dataaremeans
±SEMof10miceforeachgroup. ∗P<. 01versussham; ◦P<. 01
DNBS WT.
various intestinal conditions associated with diarrhea such
as celiac disease [32], IBD [33], infectious gastroenteritis
[34–36], and food intolerance or allergy [37, 38]. It is
possibletoassessintestinalpermeabilityinvivobymeasuring
the urinary excretion of hydrosoluble and not degradable
probes given orally. The lactulose/mannitol (L/M) test uses
a mixture of two unmetabolized sugars, minimizing the
inﬂuence of variables such as gastric emptying, intestinal
motility, and renal function, which aﬀect both markers
equally. Moreover, it is a nontoxic, noninvasive test and the
laboratory procedure is simple and inexpensive [39]. The
L/M test is used in the diagnosis and follow-up of celiac [40–
42] and Crohn’s disease [43, 44].
As clearly demonstrated in this study, the absence of
PPAR-α in mice (animals with the PPAR-αKO phenotype)
resulted in a pronounced increase in L/M ratios observed
at 4 days after DNBS administration in comparison with
PPAR-αWT mice. Moreover, when WT and PPAR-αKO mice
were treated with VB, a signiﬁcant inhibition in L/M ratios
w a so b s e r v e di nW Tb u tn o ti nP P A R - αKO mice. Is also
important to point out that the genetic inhibition of PPAR-
α did not change the physiological L/M ratios in the sham-
operated mice.
The results here described clearly indicate that the anti-
inﬂammatory eﬃcacy of VB treatment is favored by the
presence of PPAR-α. Moreover, previous studies showed that
PPAR-α agonists exert some anti-inﬂammatory activity [45].
The eﬃcacy of VB treatment in inﬂammatory and autoim-
mune diseases is an important therapeutic subject and while
some patients obtain clinical beneﬁts from treatment, others
are not responsive or even resistant to therapy. Results
discussed here suggest a new mechanism contributing to
determine the full VB eﬃcacy and suggest future studies
aimed to analyze the possible relevance of PPAR-α in other
human inﬂammatory disease models, such as sepsis.
In conclusion, our results clearly indicate that PPAR-α
can contribute by enhancing the anti-inﬂammatory activity
of VB in DNBS-induced inﬂammatory bowel disease model.
These observations suggest that VB could use the same
pathway of PPAR-α agonists in inﬂammatory diseases for its
beneﬁcial eﬀects.
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